
Agilent Technologies A
€ 98.99
1.66%
Quartalsbericht 2025-Q4
hinzugefügt 03.03.2026
Agilent Technologies Betriebsaufwand 2011-2026 | A
Betriebsaufwand Jährlich Agilent Technologies
| 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 | 2014 | 2013 | 2012 | 2011 |
|---|---|---|---|---|---|---|---|---|---|---|
| - | 1.99 B | 1.86 B | 1.76 B | 1.57 B | 1.58 B | 1.52 B | 2.76 B | 2.58 B | 2.48 B | 2.46 B |
Alle Zahlen in USD-Währung
Indikatorenreichweite aus Jahresberichten
| Höchstwert | Mindestwert | Durchschnitt |
|---|---|---|
| 2.76 B | 1.52 B | 2.06 B |
Betriebsaufwand anderer Aktien in der Diagnostik & Forschung
| Name | Betriebsaufwand | Preis | % 24h | Marktkapitalisierung | Land | |
|---|---|---|---|---|---|---|
|
Centogene N.V.
CNTG
|
58 M | - | -6.23 % | $ 30.6 M | ||
|
Akumin
AKU
|
778 M | - | -17.87 % | $ 25.9 M | ||
|
Bioventus
BVS
|
217 M | $ 8.98 | 1.18 % | $ 598 M | ||
|
Brainsway Ltd.
BWAY
|
29.2 M | $ 13.87 | 1.61 % | $ 99.4 M | ||
|
Castle Biosciences
CSTL
|
59.5 M | $ 26.0 | 0.64 % | $ 722 M | ||
|
Aspira Women's Health
AWH
|
37.1 M | - | -6.19 % | $ 10.5 M | ||
|
DexCom
DXCM
|
1.89 B | $ 68.09 | 2.64 % | $ 26.6 B | ||
|
Guardant Health
GH
|
226 M | $ 88.7 | 1.74 % | $ 11.1 B | ||
|
Oxford Immunotec Global PLC
OXFD
|
59.4 M | - | - | $ 562 M | ||
|
Charles River Laboratories International
CRL
|
607 M | $ 155.4 | 2.26 % | $ 7.7 B | ||
|
CareDx, Inc
CDNA
|
411 M | $ 17.57 | 1.44 % | $ 936 M | ||
|
ICON Public Limited Company
ICLR
|
408 M | $ 101.48 | 3.96 % | $ 8.37 B | ||
|
IQVIA Holdings
IQV
|
2.94 B | $ 169.45 | 2.77 % | $ 29.1 B | ||
|
Accelerate Diagnostics
AXDX
|
77.2 M | - | -61.36 % | $ 2.46 M | ||
|
Exact Sciences Corporation
EXAS
|
2.47 B | $ 103.94 | 0.08 % | $ 19.6 B | ||
|
Global Cord Blood Corporation
CO
|
451 M | - | - | $ 399 M | ||
|
Fluidigm Corporation
FLDM
|
134 M | - | 1.08 % | $ 308 M | ||
|
Genetic Technologies Limited
GENE
|
5.91 M | - | - | $ 7.1 B | ||
|
Genetron Holdings Limited
GTH
|
983 M | - | 0.12 % | $ 80.1 M | ||
|
Fulgent Genetics
FLGT
|
181 M | $ 15.65 | 4.65 % | $ 473 M | ||
|
PRA Health Sciences, Inc.
PRAH
|
585 M | - | - | $ 10.7 B | ||
|
Biodesix
BDSX
|
106 M | $ 17.5 | 1.21 % | $ 2.27 B | ||
|
Anixa Biosciences
ANIX
|
9.98 M | $ 2.88 | 1.23 % | $ 93.5 K | ||
|
Neogen Corporation
NEOG
|
1.48 B | $ 9.37 | 2.85 % | $ 2.03 B | ||
|
Danaher Corporation
DHR
|
6.71 B | $ 194.76 | 1.76 % | $ 139 B | ||
|
Biocept
BIOC
|
21.6 M | - | -13.05 % | $ 7.29 M | ||
|
Heska Corporation
HSKA
|
131 M | - | - | $ 1.31 B | ||
|
HTG Molecular Diagnostics
HTGM
|
24.1 M | - | -20.0 % | $ 1.06 M | ||
|
Pacific Biosciences of California
PACB
|
600 M | $ 1.4 | 3.16 % | $ 420 M | ||
|
Illumina
ILMN
|
3.69 B | $ 121.73 | 2.05 % | $ 19.4 B | ||
|
Quest Diagnostics Incorporated
DGX
|
1.46 B | $ 199.39 | 0.23 % | $ 22.1 B | ||
|
QIAGEN N.V.
QGEN
|
821 M | - | - | $ 10.6 B | ||
|
BioNano Genomics
BNGO
|
41.3 M | $ 1.12 | 0.9 % | $ 1.42 M | ||
|
DarioHealth Corp.
DRIO
|
62.2 M | $ 9.28 | 10.24 % | $ 263 M | ||
|
Lantheus Holdings
LNTH
|
123 M | $ 78.71 | 0.26 % | $ 5.31 B | ||
|
Chembio Diagnostics
CEMI
|
28.5 M | - | 0.22 % | $ 16.8 M | ||
|
Check-Cap Ltd.
CHEK
|
14.1 M | - | - | $ 9.42 M | ||
|
Co-Diagnostics
CODX
|
45.3 M | $ 4.4 | 101.83 % | $ 129 M | ||
|
Medpace Holdings
MEDP
|
118 M | $ 457.78 | 0.91 % | $ 13.2 B | ||
|
Motus GI Holdings
MOTS
|
18.6 M | - | -34.28 % | $ 263 K | ||
|
Mettler-Toledo International
MTD
|
1.01 B | $ 1 218.18 | 1.62 % | $ 25.1 B | ||
|
Celcuity
CELC
|
113 M | $ 114.64 | -0.23 % | $ 4.52 B | ||
|
DermTech
DMTK
|
104 M | - | -11.32 % | $ 2.94 M | ||
|
Twist Bioscience Corporation
TWST
|
116 M | $ 46.28 | 2.82 % | $ 2.77 B | ||
|
National Research Corporation
NRC
|
38.5 M | $ 18.07 | 3.85 % | $ 404 M | ||
|
NeoGenomics
NEO
|
430 M | $ 8.41 | 2.06 % | $ 1.08 B | ||
|
Invitae Corporation
NVTA
|
343 M | - | - | $ 21.2 M | ||
|
Enzo Biochem
ENZ
|
47.4 M | - | -8.98 % | $ 14.8 K | ||
|
Natera
NTRA
|
258 M | $ 201.38 | 1.87 % | $ 19.8 B |